Influence of beta-blockers on endothelial function: A meta-analysis of randomized controlled trials

Cardiology Journal

Volumn 22, Issue 6, 2015, Pages 708-716

  Peller, Michał ^a   Ozierański, Krzysztof ^a   Balsam, Paweł ^a   Grabowski, Marcin ^a   Filipiak, Krzysztof J ^a   Opolski, Grzegorz ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Arterial hypertension; Beta blocker; Endothelial dysfunction; Flow mediated dilation; Meta analysis

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CARVEDILOL; HYDROCHLOROTHIAZIDE; IVABRADINE; LOSARTAN; METOPROLOL; NEBIVOLOL; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN; ZOFENOPRIL;

ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); ENDOTHELIAL DYSFUNCTION; FOLLOW UP; HUMAN; META ANALYSIS; PERIPHERAL ARTERIAL TONOMETRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; DRUG EFFECTS; HYPERTENSION; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASODILATION;

EID: 84983140563     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.a2015.0042     Document Type: Article

References (33)

1. Halcox JP, Schenke WH, Zalos G et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation, 2002; 106: 653–658.
2. Task Force Members, ESC Committee for Practice Guidelines. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J, 2013; 34: 2949–3003.
3. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J, 2012; 33: 1787–1847.
4. Ritter JM. Nebivolol: Endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol, 2011; 38: (suppl. 3): S13–S16.
5. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med, 1995; 332: 488–493.
6. National Collaborating Centre for Methods and Tools (2008). Quality Assessment Tool for Quantitative Studies. Hamilton, ON: McMaster University. (Updated 13 April, 2010).
7. Higgins JPT, Green S eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
8. Koh KK, Quon MJ, Han SH et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol, 2010; 140: 73–81.
9. Lin ZP, Dong M, Liu J. Bisoprolol improved endothelial function and myocardium survival of hypertension with stable angina: A randomized double-blinded trial. Eur Rev Med Pharmacol Sci, 2013; 17: 794–801.
10. Pasini AF, Garbin U, Stranieri C. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens, 2008; 21: 1251–1257.
11. Lekakis JP, Protogerou A, Papamichael C et al. Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease. Cardiovasc Drugs Ther, 2005; 19: 277–281.
12. Ghiadoni L, Magagna A, Versari D et al. Different Effect of Antihypertensive Drugs on Conduit Artery Endothelial Function. Hypertension, 2007; 41: 1281–1286.
13. Nerla R, Di Franco A, Pitocco D et al. Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients. Heart, 2012; 98: 1812–1816.
14. Zepeda RJ, Castillo R, Rodrigo R et al. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension. Basic Clin Pharmacol Toxicol, 2012; 111: 309–316
15. Jawa A, Nachimuthu S, Pendergrass M, Asnani S, Fonseca V. Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. J Diabetes Complications, 2008; 22: 303–308.
16. Kosch M, Levers A, Lang D, et al. A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension. Nephrol Dial Transplant, 2008 23: 2280–2285.
17. Matsuda Y, Akita H, Terashima M, Shiga N, Kanazawa K, Yokoyama M. Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J, 2000; 140: 753–759.
18. Bank AJ, Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Hypertens, 2007; 20: 777–783.
19. Xiaozhen H, Yun Z, Mei Z. Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy. Blood Pressure, 2010; 19: 40–47.
20. Espinola-Klein C, Weisser G, Jagodzinski A et al. Beta-blockers in patients with intermittent claudication and arterial hypertension. Results From the Nebivolol or Metoprolol in Arterial Occlusive Disease Trial. Hypertension, 2007; 58: 148–154.
21. Heffernan KS, Suryadevara R, Patvardhan EA, Mooney P, Karas RH, Kuvin JT. Effect of Atenolol vs Metoprolol Succinate on Vascular Function in Patients With Hypertension. Clin Cardiol, 2011; 34: 39–44.
22. Pasini AF, Garbin U, Nava MC et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens, 2007; 20: 443–450.
23. Flammer AJ, Hermann F, Wiesli P et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens, 2007; 25: 785–791.
24. Ward NC, Croft KD, Hodgson J, Rich L, Beilin LJ, Puddey IB. Brachial artery vasomotor function is inversely associated with 24-h ambulatory blood pressure. J Hypertens, 2004; 22: 967–972.
25. Thuillez C, Richard V. Targeting endothelial dysfunction in hypertensive subjects. J Hum Hypertens, 2005; 19 (suppl. 1): S21–25.
26. Klima Ł, Kawecka-Jaszcz K, Stolarz-Skrzypek K et al. Structure and function of large arteries in hypertension in relation to oxidative stress markers. Kardiol Pol, 2013; 71: 917–923.
27. Raij L, Hayakawa H, Coffee K, Guerra J. Effect of doxazosin on endothelial dysfunction in hypercholesterolemic/antioxidant-deficient rats. Am J Hypertens, 2007; 10: 1257–1262.
28. Feuerstein GZ, Ruffolo RR Jr.. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J, 1996; 17 (suppl. B): 24–29.
29. Chin BS, Langford NJ, Nuttall SL, Gibbs CR, Blann AD, Lip GY. Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure. Eur J Heart Fail, 2003; 5: 171–174.
30. Yu Y, Fukuda N, Yao EH et al. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. Am J Hypertens, 2008; 21: 72–77.
31. Godfraind T. Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis. Philos Trans R Soc Lond B Biol Sci, 2005; 360: 2259–2272.
32. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation, 2004; 109: 2857–2861.
33. Ferrari R. RAAS inhibition and mortality in hypertension: from pharmacology to clinical evidence. Kardiol Pol, 2013; 71: 1–7.